Evidence map›Paper›PMID 26598548›Full record

Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2016

Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.

S J Wong, T Karrison, D N Hayes, M S Kies, K J Cullen, T Tanvetyanon, A Argiris, N Takebe, D Lim, N F Saba and 7 more

Open access · bronzeAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024
    Article
  13. Review
  14. Emerging role of MYB transcription factors in cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2024
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. The Therapeutic Landscape of Salivary Gland Malignancies-Where Are We Now?International journal of molecular sciences · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 15 institutions in 4 countries.

S J WongDivision of Hematology Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee swong@mcw.edu.
T KarrisonThe University of Chicago, Chicago.
D N HayesUniversity of North Carolina at Chapel Hill, Chapel Hill.
M S KiesDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
K J CullenUniversity of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore.
T TanvetyanonH. Lee Moffitt Cancer Center & Research Institute, Tampa, USA.
A ArgirisDepartment of Medical Oncology, Hygeia Hospital, Athens, Greece University of Texas Health Science Center at San Antonio, San Antonio.
N TakebeInvestigational Drug Branch, Cancer Therapy Evaluation Program, Rockville.
D LimDepartment of Medicine, City of Hope, Duarte.
N F SabaWinship Cancer Institute, Emory University, Atlanta.
F P WordenDepartment of Medicine, University of Michigan Cancer Center, Ann Arbor.
J GilbertDepartment of Hematology Oncology, Vanderbilt University, Nashville.
H J LenzUSC Norris Comprehensive Cancer Center, Los Angeles.
A R A RazakDepartment of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto.
J D RobertsMassey Cancer Center, Richmond.
E E VokesThe University of Chicago, Chicago.
E E W CohenUniversity of California San Diego, Moores Cancer Center, San Diego, USA.
University of Chicago · USCity of Hope · USEmory University · USMedical College of Wisconsin · USMoffitt Cancer Center · USPrincess Margaret Hospital · NZThe University of Texas Health Science Center at San Antonio · USThe University of Texas MD Anderson Cancer Center · USUniversity of California San Diego · USUniversity of Maryland, Baltimore · USUniversity of Michigan · USUniversity of North Carolina at Chapel Hill · USUSC Norris Comprehensive Cancer Center · USVanderbilt University · USVirginia Cancer Institute · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS N01-CM-62201NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundAdenoid cystic carcinoma (ACC) is a subtype of malignant salivary gland tumors (MSGT), in which 90% of cases express cKIT. Dasatinib is a potent and selective inhibitor of five oncogenic protein tyrosine kinases (PTKs)/kinase families including cKIT. We conducted a phase II study to determine the antitumor activity of dasatinib in ACC and non-ACC MSGT. PATIENTS AND

methodsIn a two-stage design, patients with progressive, recurrent/metastatic ACC (+cKIT) and non-ACC MSGT (separate cohort) were treated with dasatinib 70 mg p.o. b.i.d. Response was assessed every 8 weeks using RECIST.

resultsOf 54 patients: 40 ACC, 14 non-ACC (1, ineligible excluded); M:F = 28 : 26, median age 56 years (range 20-82 years), ECOG performance status 0 : 1 : 2 = 24 : 28 : 2, prior radiation: 44, prior chemotherapy: 21. The most frequent adverse events (AEs) (as % of patients, worst grade 2 or higher) were: fatigue (28%), nausea (19%), headache (15%), lymphopenia (7%), dyspnea (11%), alanine aminotransferase increased (7%), anorexia (7%), vomiting (7%), alkaline phosphatase increased (6%), diarrhea (6%), neutropenia (6%), and noncardiac chest pain (6%). No grade 4 AE occurred, 15 patients experienced a grade 3 AE, primarily dyspnea (5) and fatigue (4), and cardiac toxicity (1 prolonged QTc). Among ACC patients, best response to dasatinib: 1 patient (2.5%) had partial response, 20 patients (50%) had stable disease (SD) (3-14 months), 12 patients (30%) had PD, 2 withdrew, 3 discontinued therapy due to AE, and 2 died before cycle 2. Median progression-free survival was 4.8 months. Median overall survival was 14.5 months. For 14 assessable non-ACC patients, none had objective response, triggering early stopping rule. Seven had SD (range 1-7 months), 4 PD, 2 discontinued therapy due to AE, and 1 died before cycle 2.

conclusionAlthough there was only one objective response, dasatinib is well tolerated, with tumor stabilization achieved by 50% of ACC patients. Dasatinib demonstrated no activity in non-ACC MSGT.

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Adenoid CysticDasatinibDisease-Free SurvivalFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalProtein Kinase InhibitorsProto-Oncogene Proteins c-kitSalivary Gland NeoplasmsTreatment OutcomeAntineoplastic AgentsDasatinibProtein Kinase InhibitorsProto-Oncogene Proteins c-kitadenoid cystic carcinomacKITdasatinibmalignant salivary gland cancerphase II

Identifiers

PMID26598548
PMCPMC4722891
OpenAlexW2178274441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.